Atomwise Stock

atomwise.comBioTechFounded: 2012Funding to Date: $57.84MM

Atomwise is the developer of first deep learning technology designed for structure-based small molecule drug discovery.

Register for Details

For more details on financing and valuation for Atomwise, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Abraham Heifets Ph.D
Co-Founder & Chief Executive Officer
Izhar Wallach Ph.D
Co-Founder & Chief Technology Officer
Han Lim
Vice President and Global Head of Partnering

Board Members

Adam Seabrook
B Capital Group
Gavin Teo
B Capital Group
Kiersten Stead Ph.D
Monsanto Growth Ventures
Matthew Ocko
Data Collective

Other companies like Atomwise in the BioTech sector

Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.89B
Sector
Last Round Est. Valuation
$872.62MM
Sector
Last Round Est. Valuation
$486.63MM
Sector
Last Round Est. Valuation
$186.12MM
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$185MM

News

Atomwise, a company leveraging AI and machine learning to accelerate drug discovery, has raised $123 million in venture capital.
The folks behind Atomwise's spinout X-37 like to think in cosmological metaphors, and you can think of their AI drug development model as probes sent into space from a central station. That station just got $14.5 million in Series A funding from DCVC Bio, Alpha Intelligence Capital and Hemi Ventures